Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Utilizing the innate immune system to deliver therapeutic agents

a technology of innate immune system and therapeutic agent, applied in the direction of antibody medical ingredients, organic active ingredients, peptide/protein ingredients, etc., to achieve the effect of promoting neuronal health or stability

Inactive Publication Date: 2020-04-09
DREXEL UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patent describes the use of particles and drugs to improve the delivery of molecules to the brain. The particles enhance the escape of molecules from endosomes, which are cellular structures, and the drugs promote the health and stability of neurons. Examples of such particles include molecules like methylene blue, mannitol, bradykinin, serotonin, and others. The drugs can also include brain-derived neurotrophic factor, nerve growth factor, calpain inhibitors, and flavonoids. Overall, this technology allows for better delivery of molecules to the brain and improved treatment for neurological diseases.

Problems solved by technology

Efficient drug delivery to a specific site of injury within a region of the body of the patient in order to minimize off-target effects is a continuing challenge in the pharmaceutical arts.
This is especially challenging in regions of the body, such as the brain, to which access is highly regulated by endogenous systems.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Utilizing the innate immune system to deliver therapeutic agents
  • Utilizing the innate immune system to deliver therapeutic agents
  • Utilizing the innate immune system to deliver therapeutic agents

Examples

Experimental program
Comparison scheme
Effect test

experimental examples

[0119]The invention is further described in detail by reference to the following experimental examples. These examples are provided for purposes of illustration only, and are not intended to be limiting unless otherwise specified. Thus, the invention should in no way be construed as being limited to the following examples, but rather, should be construed to encompass any and all variations which become evident as a result of the teaching provided herein.

[0120]Without further description, it is believed that one of ordinary skill in the art can, using the preceding description and the following illustrative examples, make and utilize the compounds of the present invention and practice the claimed methods. The following working examples therefore, specifically point out the preferred embodiments of the present invention, and are not to be construed as limiting in any way the remainder of the disclosure.

example 1

are Stable in the Intracellular Space of Macrophages Over Time

[0121]In order to test if monocyte-derived macrophages (MDM) can be reprogrammed and used as a therapeutic following traumatic brain injury (TBI), polymeric microparticles that can promote and maintain an anti-inflammatory MDM phenotype were fabricated. After administering different types of polymeric particles to MDM, it was determined that poly(lactic-co-glycolic acid) (PLGA) microparticles loaded with a model drug were detectable intracellularly for more than two weeks and slowly released drug to the cell's cytoplasm over that time frame.

[0122]To test if intracellular PLGA particles were capable of preserving a drug's bioactivity, PLGA particles loaded with dexamethasone (DEX) were fabricated because DEX is anti-inflammatory, promotes phagocytosis, crosses membranes, and has cytoplasmic receptors. After introducing DEX-loaded particles to MDM, particles were rapidly phagocytosed, stored intracellularly, and released DE...

example 2

ular Particles Release Model Drugs, which Localize with Cytoplasmic Receptors

[0127]The particle longevity data suggests that the PLGA particles are durable enough to survive intracellularly for over two weeks. However, it is important to test if particles were able to release drugs to the cytoplasm of cells. Cytoplasmic delivery of molecules is important because the cytoplasm houses a vast number of molecules that could be regulated by therapeutics. In order to test if a drug could be delivered to the cytoplasm, PLGA particles loaded with the model drug TRITC were utilized. Particles were administered to cells for four hours and any non-phagocytosed particles were removed from the system. After five days, the cells were fixed and stained with the cytoplasmic, glucocorticoid receptor BuGR2. Following immunocytochemical staining, the cells were imaged on an OLYMPUS® confocal microscope. Signal for nuclei (DAPI, FIGS. 5A and 5D), particles (TRITC, FIGS. 5B and 5D), and the cytoplasm ma...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Lengthaaaaaaaaaa
Nanoscale particle sizeaaaaaaaaaa
Hydrophobicityaaaaaaaaaa
Login to View More

Abstract

In one aspect, the invention provides a composition comprising at least one monocyte comprising an agent that increases monocyte homing to a site of injury, and an effective amount of a drug. In another aspect, the invention provides a method of using the composition to deliver a drug to a site of injury.

Description

CROSS REFERENCE TO RELATED APPLICATIONS[0001]The application claims priority to U.S. Provisional Patent Application No. 62 / 512,284, filed May 30, 2017, which is incorporated herein by reference in its entirety.STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT[0002]This invention was made with government support under Contract No. R01 HL130037 awarded by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH). The government has certain rights in the invention.BACKGROUND OF THE INVENTION[0003]Efficient drug delivery to a specific site of injury within a region of the body of the patient in order to minimize off-target effects is a continuing challenge in the pharmaceutical arts. This is especially challenging in regions of the body, such as the brain, to which access is highly regulated by endogenous systems. There is a need in the art for compositions and methods that facilitate the delivery of therapeutic agents to difficult-to...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K35/15A61K9/16A61K31/573
CPCA61K35/15A61K9/1647A61K31/573A61K39/39A61K31/4045A61K9/00A61K31/5415A61K31/7004A61K38/043A61K38/185A61K38/2026A61K38/2066A61K38/217A61K39/4622A61K39/4614A61K39/46432A61K2300/00
Inventor SPILLER, KARA L.WOFFORD, KATHRYN L.
Owner DREXEL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com